Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis

Endocrine-Related Cancer

Volumn 17, Issue 1, 2010, Pages 7-16

  Rodríguez Antona, Cristina ^a,b   Pallares, Judith ^c   Montero Conde, Cristina ^a   Inglada Pérez, Lucia ^a,b   Castelblanco, Esmeralda ^c   Landa, Iñigo ^a   Leskelä, Susanna ^a   Leandro García, Luis J ^a   López Jiménez, Elena ^a   Letón, Rocío ^a   Cascón, Alberto ^a,b   Lerma, Enrique ^d   Martin, M Carmen ^a   Carralero, M Carmen ^a   Mauricio, Didac ^c   Cigudosa, Juan Cruz ^a,b   Matias Guiu, Xavier ^c   Robledo, Mercedes ^a,b  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^c HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN RET; PROTEIN TYROSINE KINASE; VASCULOTROPIN RECEPTOR 2;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE ACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; THYROID MEDULLARY CARCINOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEUPLOIDY; CARCINOMA, MEDULLARY; CHROMOSOMES, HUMAN, PAIR 7; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-1; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR, EPIDERMAL GROWTH FACTOR; THYROID NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; YOUNG ADULT;

EID: 77449155462     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-08-0304     Document Type: Article

References (37)

1. Akslen LA & Varhaug JE 1995 Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and patient survival. Cancer 76 1643-1654.
2. Bergholm U, Bergstrom R & Ekbom A 1997 Long-term follow-up of patients with medullary carcinoma of the thyroid. Cancer 79 132-138.
3. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A et al. 2001 Guidelines for diagnosis and therapy of MEN type 1 and type 2. Journal of Clinical Endocrinology and Metabolism 86 5658-5671.
4. Cascon A, Ruiz-Llorente S, Rodriguez-Perales S, Honrado E, Martinez-Ramirez A, Leton R, Montero-Conde C, Benitez J, Dopazo J, Cigudosa JC et al. 2005 A novel candidate region linked to development of both pheochromocytoma and head/neck paraganglioma. Genes, Chromosomes and Cancer 42 260-268.
5. Ceccherini I, Bocciardi R, Luo Y, Pasini B, Hofstra R, Takahashi M & Romeo G 1993 Exon structure and flanking intronic sequences of the human RET proto-oncogene. Biochemical and Biophysical Research Communications 196 1288-1295.
6. Chen BK, Ohtsuki Y, Furihata M, Takeuchi T, Iwata J, Liang SB & Sonobe H 1999 Co-overexpression of p53 protein and epidermal growth factor receptor in human papillary thyroid carcinomas correlated with lymph node metastasis, tumor size and clinicopathologic stage. International Journal of Oncology 15 893-898.
7. Ciardiello F & Tortora G 2008 EGFR antagonists in cancer treatment. New England Journal of Medicine 358 1160-1174.
8. Cote GJ & Gagel RF 2003 Lessons learned from the management of a rare genetic cancer. New England Journal of Medicine 349 1566-1568.
9. Croyle M, Akeno N, Knauf JA, Fabbro D, Chen X, Baumgartner JE, Lane HA & Fagin JA 2008 RET/PTCinduced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR. Cancer Research 68 4183-4191.
10. Elliott DD, Sherman SI, Busaidy NL, Williams MD, Santarpia L, Clayman GL & El-Naggar AK 2008 Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification. Human Pathology 39 15-20.
11. Giraudet AL, Vanel D, Leboulleux S, Auperin A, Dromain C, Chami L, Ny Tovo N, Lumbroso J, Lassau N, Bonniaud G et al. 2007 Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. Journal of Clinical Endocrinology and Metabolism 92 4185-4190.
12. Haddad RI, Krebs AD, Vasselli J, Paz-Ares LG & Robinson B 2008 A phase II open-label study of vandetanib in patients with locally advanced or metastatic hereditary medullary thyroid cancer. Journal of Clinical Oncology 26 6024.
13. Klein M, Picard E, Vignaud JM, Marie B, Bresler L, Toussaint B, Weryha G, Duprez A & Leclere J 1999 Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma. Journal of Endocrinology 161 41-49.
14. Leboulleux S, Baudin E, Travagli JP & Schlumberger M 2004 Medullary thyroid carcinoma. Clinical Endocrinology 61 299-310.
15. Lee DH, Lee GK, Kong SY, Kook MC, Yang SK, Park SY, Park SH, Keam B, Park do J, Cho BY et al. 2007 Epidermal growth factor receptor status in anaplastic thyroid carcinoma. Journal of Clinical Pathology 60 881-884.
16. Lim DJ, Baek KH, Lee YS, Park WC, Kim MK, Kang MI, Jeon HM, Lee JM, Yun-Cha B, Lee KW et al. 2007 Clinical, histopathological, and molecular characteristics of papillary thyroid microcarcinoma. Thyroid 17 883-888.
17. Lin JD & Chao TC 2005 Vascular endothelial growth factor in thyroid cancers. Cancer Biotherapy & Radiopharmaceuticals 20 648-661.
18. Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K, Vasko V, El-Naggar AK & Xing M 2008 Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. Journal of Clinical Endocrinology and Metabolism 93 3106-3116.
19. Lopez JP, Wang-Rodriguez J, Chang CY, Sneh G, Yu MA, Pardo FS, Aguilera J & Ongkeko WM 2008 Gefitinib (Iressa) potentiates the effect of ionizing radiation in thyroid cancer cell lines. Laryngoscope 118 1372-1376.
20. Mitsiades CS, Kotoula V, Poulaki V, Sozopoulos E, Negri J, Charalambous E, Fanourakis G, Voutsinas G, Tseleni-Balafouta S & Mitsiades N 2006 Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis. Journal of Clinical Endocrinology and Metabolism 91 3662-3666.
21. Modigliani E,Cohen R,Campos JM, Conte-Devolx B,Maes B, Boneu A, Schlumberger M, Bigorgne JC, Dumontier P, Leclerc L et al. 1998 Prognostic factors for survival and for biochemical cure inmedullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'etude des tumeurs a calcitonine. Clinical Endocrinology 48 265-273.
22. Murakawa T, Tsuda H, Tanimoto T, Tanabe T, Kitahara S & Matsubara O 2005 Expression of KIT, EGFR, HER-2 and tyrosine phosphorylation in undifferentiated thyroid carcinoma: implication for a new therapeutic approach. Pathology International 55 757-765.
23. Nagy R, Sweet K & Eng C 2004 Highly penetrant hereditary cancer syndromes. Oncogene 23 6445-6470.
24. Pallares J, Rojo F, Iriarte J, Morote J, Armadans LI & de Torres I 2006 Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues. Histology and Histopathology 21 857-865.
25. Pennell NA, Daniels GH, Haddad RI, Ross DS, Evans T, Wirth LJ, Fidias PH, Temel JS, Gurubhagavatula S, Heist RS et al. 2008 A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid 18 317-323.
26. Randolph GW & Maniar D 2000 Medullary carcinoma of the thyroid. Cancer Control 7 253-261.
27. Schiff BA, McMurphy AB, Jasser SA, Younes MN, Doan D, Yigitbasi OG, Kim S, Zhou G, Mandal M, Bekele BN et al. 2004 Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clinical Cancer Research 10 8594-8602.
28. Schuffenecker I, Virally-Monod M, Brohet R, Goldgar D, Conte-Devolx B, Leclerc L, Chabre O, Boneu A, Caron J, Houdent C et al. 1998 Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. Groupe D'etude des Tumeurs a Calcitonine. Journal of Clinical Endocrinology and Metabolism 83 487-491.
29. Sharma SV, Bell DW, Settleman J & Haber DA 2007 Epidermal growth factor receptor mutations in lung cancer. Nature Reviews. Cancer 7 169-181.
30. Turner HE, Harris AL, Melmed S & Wass JA 2003 Angiogenesis in endocrine tumors. Endocrine Reviews 24 600-632.
31. Tuttle RM, Fleisher M, Francis GL & Robbins RJ 2002 Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation. Journal of Clinical Endocrinology and Metabolism 87 1737-1742.
32. Uchino S, Noguchi S, Yamashita H, Sato M, Adachi M, Yamashita H, Watanabe S, Ohshima A, Mitsuyama S, Iwashita T et al. 1999 Somatic mutations in RET exons 12 and 15 in sporadic medullary thyroid carcinomas: different spectrum of mutations in sporadic type from hereditary type. Japanese Journal of Cancer Research 90 1231-1237.
33. Vieira JM, Santos SC, Espadinha C, Correia I, Vag T, Casalou C, Cavaco BM, Catarino AL, Dias S & Leite V 2005 Expression of vascular endothelial growth factor (VEGF) and its receptors in thyroid carcinomas of follicular origin: a potential autocrine loop. European Journal of Endocrinology 153 701-709.
34. Wells SA Jr, Baylin SB, Johnsrude IS, Harrington DP, Mendelsohn G, Ontjes DJ & Cooper CW 1982 Thyroid venous catheterization in the early diagnosis of familial medullary thyroid carcinoma. Annals of Surgery 196 505-511.
35. Wells SA, Gosnell JE, Gagel RF, Moley JF, Pfister DG, Sosa JA, Skinner M, Krebs A, Hou J & Schlumberger M 2007 Vandetanib in metastatic hereditary medullary thyroid cancer: follow-up results of an open-label phase II trial. Journal of Clinical Oncology 25 6018.
36. Wiseman SM, Masoudi H, Niblock P, Turbin D, Rajput A, Hay J, Bugis S, Filipenko D, Huntsman D & Gilks B 2007 Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. Annals of Surgical Oncology 14 719-729.
37. Zhang X & Chang A 2008 Molecular predictors of EGFRTKI sensitivity in advanced non-small cell lung cancer. International Journal of Medical Sciences 5 209-217.